Results 11 to 20 of about 2,997 (217)

ImmunoPET imaging of Trop2 in patients with solid tumours

EMBO Molecular Medicine
Accurately predicting and selecting patients who can benefit from targeted or immunotherapy is crucial for precision therapy. Trophoblast cell surface antigen 2 (Trop2) has been extensively investigated as a pan-cancer biomarker expressed in various ...
Wei Huang, You Zhang, Min Cao, Yanfei Wu, Feng Jiao, Zhaohui Chu, Xinyuan Zhou, Lianghua Li, Dongsheng Xu, Xinbing Pan, Yihui Guan, Gang Huang, Jianjun Liu, Fang Xie, Weijun Wei   +14 more
doaj   +4 more sources

Pre-clinical Imaging of Invasive Candidiasis Using ImmunoPET/MR [PDF]

Frontiers in Microbiology, 2018
The human commensal yeast Candida is the fourth most common cause of hospital-acquired bloodstream infections, with Candida albicans accounting for the majority of the >400,000 life-threatening infections annually.
Hassan O. J. Morad, Anna-Maria Wild, Anna-Maria Wild, Stefan Wiehr, Stefan Wiehr, Genna Davies, Andreas Maurer, Bernd J. Pichler, Christopher R. Thornton   +8 more
doaj   +7 more sources

Quantification of ⁸⁹Zr-immunoPET:Methodological considerations. [PDF]

Nuclear Medicine and Biology
PURPOSE: Clinical 89Zr-immunoPET relies on semi-quantitative metrics, such as standardised uptake values (SUV) from static imaging at delayed time points. However, SUV can misinterpret target engagement as it ignores plasma and tissue kinetics.
Brouwers, Adrienne H, Lammertsma, Adriaan A, Li, Zekai, Lub-de Hooge, Marjolijn N, Mohr, Philipp, Tsoumpas, Charalampos, van Sluis, Joyce, van Winkel, Claudia A J   +7 more
core   +3 more sources

Trop2-targeted immunoPET ligands. [PDF]

Am J Nucl Med Mol Imaging
Trop2 is overexpressed in various tumors and serves as a key biomarker. Targeted immunoPET ligands, mainly developed from Trop2 monoclonal antibodies and nanobodies, provide the landscape of heterogeneous expression of Trop2 in tumors, which has great ...
Liang SH.
europepmc   +3 more sources

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

Frontiers in Medicine, 2022
Immuno-positron emission tomography (immunoPET) is a molecular imaging modality combining the high sensitivity of PET with the specific targeting ability of monoclonal antibodies.
Reyhaneh Manafi-Farid, Bahar Ataeinia, Shaghayegh Ranjbar, Zahra Jamshidi Araghi, Mohammad Mobin Moradi, Christian Pirich, Mohsen Beheshti   +6 more
doaj   +3 more sources

DLL3-targeted immunoPET and radioimmunotherapy ligands. [PDF]

Am J Nucl Med Mol Imaging
DLL3 is overexpressed on the cell surface of NENs, such as SCLC and NEPC, but notably restricted to cytoplasm with low expression levels in normal adult human tissues.
Liang SH.
europepmc   +3 more sources

From Desferrioxamine B Umpolung to an Enantiopure Bifunctional Chelator for ⁸⁹Zr-immunoPET. [PDF]

Chemistry
Functional group transformations were performed at the pendent amine residue of desferrioxamine B (DFO), the commercial siderophore used in various medical applications, including iron decorporation, antibiotic development, and molecular imaging.
Zujew L, Raibaut L, Chambron JC.
europepmc   +3 more sources

ImmunoPET: Concept, Design, and Applications.

Chemical Reviews, 2020
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) and the inherent sensitivity of PET technique. A variety of radionuclides and mAbs
Weijun Wei, Z. Rosenkrans, Jianju Liu, Gang Huang, Quan-Yong Luo, W. Cai   +5 more
semanticscholar   +4 more sources

⁸⁹Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe [PDF]

Molecules, 2020
High expression levels of the tumor-associated antigen MUC1 have been correlated with tumor aggressiveness, poor response to therapy, and poor survival in several tumor types, including breast, pancreatic, and epithelial ovarian cancer. Herein, we report
Kimberly Fung, Delphine Vivier, Outi Keinänen, Elaheh Khozeimeh Sarbisheh, Eric W. Price, Brian M. Zeglis   +5 more
doaj   +3 more sources

CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients [PDF]

Biomarker Research
Cell- and antibody-based CD19-directed therapies have demonstrated great potential for treating B-cell non-Hodgkin lymphoma (B-NHL). However, all these approaches suffer from limited response rates and considerable toxicity.
Dominik Sonanini, Johannes Schwenck, Simone Blaess, Julia Schmitt, Andreas Maurer, Walter Ehrlichmann, Malte Ritter, Julia Skokowa, Manfred Kneilling, Gundram Jung, Falko Fend, Simon Krost, Christian M. Seitz, Peter Lang, Gerald Reischl, Rupert Handgretinger, Christian la Fougère, Bernd J. Pichler   +17 more
doaj   +2 more sources